buyouts news from FiercePharma
News
Zimmer mulls $250M in doc-contract buyouts
You've heard of sports teams buying out their coaches' contracts. Well, now there's a device maker considering buying out its deals with surgeons. In a move designed to clear up legal troubles
Read more...Lilly wants to buy out 500 workers
Add up to 500 Eli Lilly workers to the pharma layoff toll. The Indianapolis-based pharma plans to offer buyout packages Read more...
Falling dollar, falling drugmaker prices
Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...
Vasella touts Novartis' diversification
Novartis CEO Daniel Vasella (photo) talked up his company's prospects in an interview with the Swiss weekly Sonntag, Read more...
What did Vasella see in Alcon?
Just why would Novartis pay $11 billion for one-fourth of an eye-care company and promise another $28 Read more...
Novartis pledges $39B for Alcon
In a bid to diversify its business away from traditional pharma, Novartis has bought a 25 percent stake in Alcon and is eyeing the purchase of another 52 percent in 2010. The Swiss drugmaker paid Read more...
Roche sales surpass Novartis'
Eat dust, Novartis. Roche just posted sales of $42.2 billion, $2.4 billion more than its Swiss rival's $39.8 billion. Strong sales of its cancer drugs helped boost profits by 25 percent to $10.48 Read more...
Pharma noshes at the biotech buffet
If 2007 was the year pharma woke up to biotech, then 2008 will be time for brunch. Drug makers will continue to serve themselves from the biologics buffet, whether by gobbling up entire companies or Read more...
Pharma goes mad for biotech deals
One word: Biotech. As if acting on some wise elder's tip-off, Pharma got its biotech groove on in Read more...
ALSO NOTED: Byetta data backs stand-alone app; Watson, Novartis settle suit;
> Amylin Pharmaceuticals says it has the data to back an application to make Byetta a stand-alone therapy for diabetes. Read more...
Get more buyouts coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends